A more recent study reveals that in ARID1A deficiency ovarian cancer, HDAC6 inhibition synergizes with anti-PD-L1 immune checkpoint blockade, and ARID1A directly repressed the transcription of the CD274 (encoding PD-L1) gene (108). Here, ARID1A is linked to ovarian carcinoma.